News and features

Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.

If you’re a journalist and want to find out more, you can contact our media relations team.

t-cell rhs
ICR alumnus Professor Jacques Miller awarded the Japan Prize

01/02/18

Professor Jacques Miller has been awarded the prestigious Japan Prize for his discovery of the role of the thymus and the two types of white blood cell involved in the adaptive immune system – a discovery that laid the groundwork for much of the field of immunology.
Myeloma of sphenoid sinus. Wellcome Images / Creative Commons by-nc-nd 4.0
Blocking cancer stress signal shows promise in bone marrow cancer

01/02/18

Potential new drugs that block a safeguard used by cancer cells to stay alive in stressful conditions have shown promise against myeloma, a cancer of white blood cells made in the bone marrow, a new study reports.
Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAID
Blood test could indicate which patients will respond to immunotherapy

30/01/18

The test gives a measure of a patient’s immune system health by comparing the number of neutrophils with the number of lymphocytes.
Radiotherapy suite (Joe Dunckley for the ICR, 2014)
Viral gene therapy could improve results from breast reconstruction surgery after cancer treatment

24/01/18

A new type of gene therapy delivered using a virus could protect healthy tissues from the harmful side-effects of radiotherapy after cancer treatment, a new study reports.
ICR Logo
Exposure to light at night does not increase breast cancer risk, major new study suggests

23/01/18

The prospective analysis of 105,866 women provides evidence against the 40 year old proposal that night-time light levels and breast cancer risk are linked.
ICR Logo
New treatment strategy could overcome drug resistance in testicular cancer

22/01/18

Men with testicular cancers called testicular germ cell tumours could benefit from a new combination of treatments if their chemotherapy stops working.
ICR Logo
Scientists zoom in to watch DNA code being read

17/01/18

Scientists have unveiled incredible images of how the DNA code is read and interpreted – revealing new detail about one of the fundamental processes of life.
Sir Richard Doll building in Sutton
The ICR and Cancer Research UK join forces with leading science and technology company in new drug discovery alliance

17/01/18

The deal follows previous drug discovery collaborations and a more recent successful target validation collaboration between Merck and Cancer Research UK’s Cancer Therapeutics Unit at the ICR.
Jonny Pettinger and others posing with cricket bats (547x410)
ICR PhD student chosen to speak at joint UK-India conference

16/01/18

Jonny Pettinger was one of just eight PhD students chosen from across the UK to speak, and was also given the chance to undertake a two-week research project.
logo
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant​​ advanced breast cancer

12/01/18

The Institute of Cancer Research, London, strongly welcomes the news that olaparib has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer.
Radiotherapy IMRT Jan Chlebik/the ICR
Scientists bring innovative microbeam radiation therapy for cancer treatment a step closer

08/01/18

Scientists have developed a new mathematical tool which will speed a smart new type of radiotherapy into the first patient trials.
Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAID
Virus could treat brain tumours by boosting immune system

03/01/18

A virus injected directly into the bloodstream could be used to treat people with aggressive brain tumours, a major new study reports.

Make a donation today

A monthly gift can help support our research over several years, so it has the maximum possible benefit for people with cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

With your generous support, we can continue making more discoveries, finding more cures, and saving more lives.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Our research centres & divisions

Through our close partnerships with The Royal Marsden and other key UK institutions, we're leading a wide breadth of cancer research across eight divisions and more than 25 research centres and strategic initiatives.